Loading...
•
Sep 30
Doximity Q2 2026 Earnings Report
Doximity reported strong financial results for its fiscal second quarter of 2026, with significant year-over-year growth in revenue, net income, and cash flows.
Key Takeaways
Doximity delivered a robust fiscal second quarter for 2026, with total revenues reaching $168.5 million, marking a 23% increase year-over-year. The company also saw substantial growth in net income, non-GAAP net income, and adjusted EBITDA, alongside strong operating and free cash flow generation. The platform's growth was attributed to new AI tools and increased prescriber engagement.
Total revenues for Q2 2026 reached $168.5 million, a 23% increase compared to the same period last year.
Net income grew to $62.1 million, with a margin of 36.8%, while non-GAAP net income was $90.0 million, representing a 53.4% margin.
Adjusted EBITDA increased by 32% year-over-year to $100.8 million, achieving an adjusted EBITDA margin of 59.8%.
Operating cash flow and free cash flow both increased by 37% year-over-year, reaching $93.9 million and $91.6 million, respectively.
Doximity
Doximity
Forward Guidance
Doximity provided guidance for the fiscal third quarter ending December 31, 2025, expecting revenue between $180 million and $181 million and Adjusted EBITDA between $103 million and $104 million. The company also updated its fiscal year 2026 guidance, projecting revenue between $640 million and $646 million and Adjusted EBITDA between $351 million and $357 million.
Positive Outlook
- Projected revenue for Q3 2026 is between $180 million and $181 million, indicating continued growth.
- Anticipated Adjusted EBITDA for Q3 2026 is between $103 million and $104 million, showing strong profitability expectations.
- Updated fiscal year 2026 revenue guidance is between $640 million and $646 million, suggesting sustained full-year growth.
- Updated fiscal year 2026 Adjusted EBITDA guidance is between $351 million and $357 million, reflecting confidence in annual profitability.
- The guidance reflects continued momentum and market leadership in the digital platform for U.S. medical professionals.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The guidance ranges, while positive, still represent a degree of uncertainty.
- Potential macroeconomic uncertainties could impact future performance.
- The company operates in a very competitive and rapidly changing environment, which could pose risks.
- New risks and uncertainties may emerge that could cause actual results to differ materially from forward-looking statements.